Full Prescribing Information, Including BOXED WARNING
Read About Twirla
Agile Therapeutics to Participate in Virtual Fireside Chat as Part of the 2021 RBC Capital Markets Global Healthcare Conference
Agile Therapeutics Reports First Quarter 2021 Financial Results
Agile Therapeutics Announces Presentation of Safety and Efficacy Data of Twirla® (Levonorgestrel and Ethinyl Estradiol) Transdermal System in Women of Differing BMI Categories at ACOG Annual Meeting
Agile Therapeutics to Report First Quarter 2021 Financial Results and Provide Business Update on Tuesday, May 4, 2020
Agile Therapeutics to Present at Upcoming March Investor Conferences
Agile Therapeutics Reports Fourth Quarter & Full Year 2020 Financial Results; Expands Loan Facility With Perceptive Advisors
Agile Therapeutics to Host Fourth Quarter and Full Year 2020 Financial Results Conference Call and Provide Corporate and Twirla Commercial Updates on Monday, March 1, 2021
Agile Therapeutics to Participate in Fireside Chat at the H.C. Wainwright BIOCONNECT 2021 Virtual Conference
Agile Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference
Our pipeline reflects our commitment to bringing women the healthcare choices they deserve. All current Agile Therapeutics product and product candidates use our proprietary Skinfusion® Technology.
Commitment. Passion. Drive.
These are the qualities that make us who we are, from the top down.
©2021 Agile Therapeutics®. All Rights Reserved.